Salvage therapy with “Dara-KDT-P(A)CE” in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
Zhou X, Ruckdeschel A, Peter J, Boeckle D, Hornburger H, Danhof S, Steinhardt MJ, Heimeshoff L, Einsele H, Kortuem KM, Rasche L (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 40
Pages Range: 202-211
Journal Issue: 2
DOI: 10.1002/hon.2949
Abstract
The multi-agent therapy “VDT-PACE” represents an established regimen in relapsed/refractory multiple myeloma (RRMM). Here, we report on our experience with a “modified VDT-PACE” incorporating new generation anti-MM agents daratumumab and carfilzomib (“Dara-KDT-P(A)CE”). We retrospectively analyzed 38 patients with RRMM treated with “Dara-KDT-P(A)CE”. The median age was 62 (range 45–82) years, and the patients were heavily pretreated with a median of 5 (range 2–12) prior lines of therapy. Twenty-one (55%) patients suffered from penta-refractory MM. High-risk cytogenetics was present in 31 (81%) patients. The patients received a median of 2 (range 1–10) cycles of this therapy, and the overall response rate (ORR) was 70%. Patients with penta-refractory MM and high-risk cytogenetics showed similar ORR of 65% and 79%, respectively. The median progression-free survival (PFS) and overall survival were 4.1 (95% CI 2.7–5.4) and 8.4 (95% CI 6.7–10.0) months, respectively. Patients with lactate dehydrogenase >250 IU/L showed significantly shorter PFS in comparison with others patients (p = 0.006). We used this regimen as bridging therapy prior to chimeric antigen receptor T-cell infusion in four patients. In conclusion, “Dara-KDT-P(A)CE” is an effective salvage therapy for patients with heavily pretreated, multi-refractory, high-risk RRMM lacking alternative options.
Involved external institutions
Germany (DE)How to cite
APA:
Zhou, X., Ruckdeschel, A., Peter, J., Boeckle, D., Hornburger, H., Danhof, S.,... Rasche, L. (2022). Salvage therapy with “Dara-KDT-P(A)CE” in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma. Hematological Oncology, 40(2), 202-211. https://doi.org/10.1002/hon.2949
MLA:
Zhou, Xiang, et al. "Salvage therapy with “Dara-KDT-P(A)CE” in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma." Hematological Oncology 40.2 (2022): 202-211.
BibTeX: Download